Literature DB >> 19113986

Detection of HIV type 1 load by the Roche Cobas TaqMan assay in patients with viral loads previously undetectable by the Roche Cobas Amplicor Monitor.

Hiroyuki Gatanaga, Kunihisa Tsukada, Haruhito Honda, Junko Tanuma, Hirohisa Yazaki, Tamayo Watanabe, Miwako Honda, Katsuji Teruya, Yoshimi Kikuchi, Shinichi Oka.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19113986     DOI： 10.1086/595707

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  10 in total

1.  Comparative performances of HIV-1 RNA load assays at low viral load levels: results of an international collaboration.

Authors:  Luke C Swenson; Bryan Cobb; Anna Maria Geretti; P Richard Harrigan; Mario Poljak; Carole Seguin-Devaux; Chris Verhofstede; Marc Wirden; Alessandra Amendola; Jurg Boni; Thomas Bourlet; Jon B Huder; Jean-Claude Karasi; Snjezana Zidovec Lepej; Maja M Lunar; Odette Mukabayire; Rob Schuurman; Janez Tomazic; Kristel Van Laethem; Linos Vandekerckhove; Annemarie M J Wensing
Journal:  J Clin Microbiol       Date:  2013-12-04       Impact factor: 5.948

2.  Cost ramifications of increased reporting of detectable plasma HIV-1 RNA levels by the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 version 1.0 viral load test.

Authors:  James H Willig; Christa R Nevin; James L Raper; Michael S Saag; Michael J Mugavero; Amanda L Willig; Jeffrey H Burkhardt; Joseph E Schumacher; Victoria A Johnson
Journal:  J Acquir Immune Defic Syndr       Date:  2010-08       Impact factor: 3.731

3.  Concordance of HIV-1 RNA Values by Amplicor and TaqMan 2.0 in Patients With Confirmed Suppression in Clinical Trials.

Authors:  Will Garner; Kirsten White; Javier Szwarcberg; Scott McCallister; Lijie Zhong; Mike Wulfsohn
Journal:  Clin Infect Dis       Date:  2015-12-21       Impact factor: 9.079

4.  Darunavir outcomes study: comparative effectiveness of virologic suppression, regimen durability, and discontinuation reasons for three-class experienced patients at 48 weeks.

Authors:  James H Willig; Inmaculada Aban; Christa R Nevin; Jiatao Ye; James L Raper; James A McKinnel; Lori L Delaitsch; Joseph M Mrus; Guy R De La Rosa; Michael J Mugavero; Michael S Saag
Journal:  AIDS Res Hum Retroviruses       Date:  2010-10-21       Impact factor: 2.205

5.  Performance evaluation of the new Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test version 2.0 for quantification of human immunodeficiency virus type 1 RNA.

Authors:  Suzan Pas; John W A Rossen; Daniel Schoener; Diana Thamke; Annika Pettersson; Reiner Babiel; Martin Schutten
Journal:  J Clin Microbiol       Date:  2010-02-17       Impact factor: 5.948

6.  Impact of HIV-1 replication on immunological evolution during long-term dual-boosted protease inhibitor therapy.

Authors:  Christoph Stephan; Valentin Bartha; Eva Herrmann; Nils von Hentig; Pavel Khaykin; Gaby Knecht; Peter Gute; Hans-Reinhard Brodt; Martin Stürmer; Annemarie Berger; Markus Bickel
Journal:  Med Microbiol Immunol       Date:  2012-09-15       Impact factor: 3.402

7.  Correction of underquantification of human immunodeficiency virus type 1 load with the second version of the Roche Cobas AmpliPrep/Cobas TaqMan assay.

Authors:  A De Bel; D Marissens; L Debaisieux; C Liesnard; S Van den Wijngaert; S Lauwers; D Piérard
Journal:  J Clin Microbiol       Date:  2010-02-17       Impact factor: 5.948

8.  Cobas ampliprep/cobas TaqMan HIV-1 v2.0 assay: consequences at the cohort level.

Authors:  Ninon Taylor; Katharina Grabmeier-Pfistershammer; Alexander Egle; Richard Greil; Armin Rieger; Bruno Ledergerber; Hannes Oberkofler
Journal:  PLoS One       Date:  2013-08-30       Impact factor: 3.240

9.  Studying patterns and predictors of HIV viral suppression using A Big Data approach: a research protocol.

Authors:  Jiajia Zhang; Bankole Olatosi; Xueying Yang; Sharon Weissman; Zhenlong Li; Jianjun Hu; Xiaoming Li
Journal:  BMC Infect Dis       Date:  2022-02-04       Impact factor: 3.090

10.  Factors Associated with Low-Level Viraemia and Virological Failure: Results from the Austrian HIV Cohort Study.

Authors:  Gisela Leierer; Katharina Grabmeier-Pfistershammer; Andrea Steuer; Maria Geit; Mario Sarcletti; Bernhard Haas; Manfred Kanatschnig; Michaela Rappold; Robert Zangerle; Bruno Ledergerber; Ninon Taylor
Journal:  PLoS One       Date:  2015-11-13       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.